RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

This is what I said recently:
<<I think the determining factor will be whether this tiny trial shows clear evidence of a clinically significant effect, and in what percentage of patients. If, for example, CX-1739 produced a halving of apnea event rate in all of the patients taking it (I'm just making that up as an extreme example), and without marked side effects, that would get a lot of attention, and you could start fantasizing about a bigger upfront payment. >>

In the latter situation, which is a best case scenario, SA might be worth more than ADHD. But I suspect that with such a small trial, it's unlikely to be that clearcut. In which case ADHD would continue to be the bigger prospect. The relative value will depend on the clarity and breadth of any SA benefit that is indicated by the data.


NeuroInvestment